SciMatic
Journals
Thesis Rep
Docs
Products
SciMatic.net
Journament
Journal Manager
Subjects
Thesis
ImProofer
Research Groups
Letter Pad
Conferences
Services
About
SciMatic
Team
Earn With Us
Join Us
Contact Us
EN
English
Türkçe
Español
Português
Pусский
Filipino
Tiếng Việt
हिन्दी
العربية
বাংলা
Deutsch
中文
Login
Keyword Connections
hiv-1
Journals
17
1
Organic & biomolecular chemistry
2
European journal of medicinal chemistry
3
Scientific reports
4
Proceedings of the National Academy of Sciences of the United States of America
5
Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
6
current pharmaceutical design
7
annals of surgical oncology
8
virus research
9
journal der deutschen dermatologischen gesellschaft = journal of the german society of dermatology : jddg
10
Journal of Virology
11
archiv der pharmazie
12
indian journal of pharmaceutical sciences
13
retrovirology
14
Antiviral research
15
journal of experimental & clinical cancer research : cr
16
il farmaco; edizione scientifica
17
Protein expression and purification
Research Groups
0
No Research Group Connected
Bibliographies
189
1
Molecular characteristic of HIV-1 CRF01_AE in Nanjing from 2015 to 2017.
2
Redefining Eligibility by Analyzing Canceled Intraoperative Radiotherapy as a Boost for Patients Undergoing Breast-Conserving Treatment.
3
Chromenone derivatives as a versatile scaffold with dual mode of inhibition of HIV-1 reverse transcriptase-associated Ribonuclease H function and integrase activity.
4
Differential neurodegenerative phenotypes are associated with heterogeneous voiding dysfunction in a coronavirus-induced model of multiple sclerosis.
5
cd8αα expression marks terminally differentiated human cd8+ t cells expanded in chronic viral infection
6
pathophysiology of cd4+ t-cell depletion in hiv-1 and hiv-2 infections
7
unexpected mutations in hiv-1 that confer resistance to the tat inhibitor didehydro-cortistatin a
8
microfluidic chip-based nucleic acid testing using gingival crevicular fluid as a new technique for detecting hiv-1 infection
9
a new role for the htlv-1 p8 protein: increasing intercellular conduits and viral cell-to-cell transmission
10
impact of the menstrual cycle on immunologic markers in hiv-infected taiwanese women
11
sensibilidade da técnica de reação em cadeia da polimerase para hiv-1 em relação à técnica de ensaio imunoenzimático
12
intrinsic immunity against retrotransposons by apobec cytidine deaminases
13
igm repertoire biodiversity is reduced in hiv-1 infection and systemic lupus erythematosus
14
inhibitors of hiv-1 reverse transcriptase—associated ribonuclease h activity
15
the cyp2b6 g516t polymorphism influences cd4+ t-cell counts in hiv-positive patients receiving antiretroviral therapy in an ethnically diverse region of the amazon
16
mangiferin, an anti-hiv-1 agent targeting protease and effective against resistant strains
17
diminished cd103 (aeb7) expression on resident t cells from the female genital tract of hiv-positive women
18
evaluation of a dry format reagent for cd4+ and cd8+ t-cell enumeration with facscount and guava polymerase chain reaction
19
natural killer cell interactions with classical and non-classical human leukocyte antigen class i in hiv-1 infection
20
role of nucleocytoplasmic rna transport during the life cycle of retroviruses
21
noncoding rnas and hiv: viral manipulation of host dark matter to shape the cellular environment
22
chapter 1. immunogenetics: genome wide association of non-progressive hiv and viral load control: hla genes and beyond
23
hiv, leukemia, and new horizons in molecular therapy
24
focus on chirality of hiv-1 non-nucleoside reverse transcriptase inhibitors
25
alkaloids from the sponge stylissa carteri present prospective scaffolds for the inhibition of human immunodeficiency virus 1 (hiv-1)
26
impact of hiv-1, hiv-2, and hiv-1+2 dual infection on the outcome of tuberculosis
27
differentially-expressed pseudogenes in hiv-1 infection
28
quantifying susceptibility of cd4+ stem memory t-cells to infection by laboratory adapted and clinical hiv-1 strains
29
fitness impaired drug resistant hiv-1 is not compromised in cell-to-cell transmission or establishment of and reactivation from latency
30
recent 5-year findings and technological advances in the proteomic study of hiv-associated disorders
31
structural basis for the antiviral activity of bst-2/tetherin and its viral antagonism
32
unique flap conformation in an hiv-1 protease with high-level darunavir resistance
33
the nef activity on hiv-1 infectivity
34
hiv-1-infection of t lymphocytes and macrophages affects their migration via nef
35
structural and molecular determinants of hiv-1 gag binding to the plasma membrane
36
The expression of HIV-1 tat in Lactococcus lactis.
37
Glycosylation of the HIV-1 Env V1V2 loop to form a native-like structure may not be essential with a nanoparticle vaccine.
38
Novel 1,5-Diphenylpyrazole Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors with Enhanced Activity versus the Delavirdine-Resistant P236L Mutant: Lead Identification and SAR of 3- and 4-Substituted Derivatives
39
Molecular Docking Study of Four Chromene Derivatives as Novel HIV-1 Integrase Inhibitors
40
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
41
HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan
42
High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014
43
Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy
44
Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
45
Evaluation of Anti-HIV-1 Integrase and Anti-Inflammatory Activities of Compounds from Betula alnoides Buch-Ham
46
HIV-1 genotypic drug resistance in patients with virological failure to single-tablet antiretroviral regimens in southern Taiwan
47
High rate of HIV-1 drug resistance in treatment failure patients in Taiwan, 2009–2014
48
Extended use of raltegravir in the treatment of HIV-1 infection: optimizing therapy
49
Investigating the distribution of HIV-1 Tat lengths present in the Drexel Medicine CARES cohort.
50
Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.
51
The global spread of HIV-1 subtype B epidemic.
52
Increased Plasma Levels of the TH2 chemokine CCL18 associated with low CD4+ T cell counts in HIV-1-infected Patients with a Suppressed Viral Load
53
Feasibility of using dried blood spots for HIV viral load testing among HIV-infected individuals in Thailand using QIAGEN QIAsymphony-artus HIV-1 platform
54
Control of the HIV-1 Load Varies by Viral Subtype in a Large Cohort of African Adults with Incident HIV-1 Infection
55
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study)
56
Inhibition of HIV-1 envelope-dependent membrane fusion by serum antilymphocyte autoantibodies is associated with low plasma viral load
57
AAV-Mediated Expression of Broadly Neutralizing and Vaccine-like Antibodies Targeting the HIV-1 Envelope V2 Region.
58
HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation.
59
Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection.
60
Characterization of T-cell responses to conserved regions of the HIV-1 proteome in BALB/c mice.
61
A short-term assessment of nascent HIV-1 transmission clusters among newly diagnosed individuals using envelope sequence-based phylogenetic analyses.
62
Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals.
63
Methamphetamine functions as a novel CD4<sup>+</sup> T-cell activator via the sigma-1 receptor to enhance HIV-1 infection
64
A SYSTEMATIC REVIEW ON THE INFLUENCE OF HLA-B POLYMORPHISMS ON HIV-1 MOTHER-TO-CHILD-TRANSMISSION.
65
Perinatal HIV-1 transmission: Fc gamma receptor variability associates with maternal infectiousness and infant susceptibility.
66
Association of HIV-1 Envelope-Specific Breast Milk IgA Responses with Reduced Risk of Postnatal Mother-to-Child Transmission of HIV-1.
67
Epidemiology of HIV-1 infection in agricultural plantation residents in Kericho, Kenya: preparation for vaccine feasibility studies.
68
Targeting HIV-1 Protease Autoprocessing for High-throughput Drug Discovery and Drug Resistance Assessment
69
Discovery of piperidine-substituted thiazolo[5,4-d]pyrimidine derivatives as potent and orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitors
70
Identification of a large, fast-expanding HIV-1 subtype B transmission cluster among MSM in Valencia, Spain.
71
Insight into analysis of interactions of saquinavir with HIV-1 protease in comparison between the wild-type and G48V and G48V/L90M mutants based on QM and QM/MM calculations.
72
Association of circulatory Tfh-like cells with neutralizing antibody responses among chronic HIV-1 subtype C infected long-term nonprogressors and progressors.
73
Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket
74
Design and Biological Evaluation of m-Xylene Thioether-stapled Short Helical Peptides Targeting the HIV-1 gp41 Hexameric Coiled-Coil Fusion Complex.
75
Correction: Conformational states of HIV-1 reverse transcriptase for nucleotide incorporation vs pyrophosphorolysis - Binding of Foscarnet (ACS Chemical Biology (2016) 11: 8 (2158-2164) DOI: 10.1021/acschembio.6b00187)
76
Use of Dried Blood Spots to Elucidate Full-Length Transmitted/Founder HIV-1 Genomes
77
Transmission dynamics of HIV-1 subtype B strains in Indonesia.
78
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
79
Contribution of the Microbiota to Intestinal Homeostasis and its Role in the Pathogenesis of HIV-1 Infection.
80
Enzymatic Glycosylation of Triazole-Linked GlcNAc/Glc-Peptides: Synthesis, Stability and Anti-HIV Activity of Triazole-Linked HIV-1 gp41 Glycopeptide C34 Analogues
81
Synthesis of novel benzofuran and related benzimidazole derivatives for evaluation ofin vitro anti-HIV-1, anticancer and antimicrobial activities
82
Large transmission clusters of HIV-1 main genotypes among HIV-1 individuals before antiretroviral therapy in the Hebei province, China.
83
Treatment Adherence And Persistence Among HIV-1 Patients Newly Starting Treatment.
84
Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120.
85
Performance of an Alternative Laboratory-Based HIV Diagnostic Testing Algorithm Using HIV-1 RNA Viral Load.
86
Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4–8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011–12 and 2012–13
87
Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance.
88
Epidemiology of transmitted drug resistance mutations in an HIV-1 subtype C high-prevalence setting and impact on 1-year virological failure
89
Stability behaviour of antiretroviral drugs and their combinations. 11: Characterization of interaction products of zidovudine and efavirenz, and evaluation of their anti HIV-1 activity, and physiochemical and ADMET properties
90
Proton transfer and drug binding details revealed in neutron diffraction studies of wild-type and drug resistant HIV-1 protease
91
Following the path: Increasing trends of HIV-1 drug resistance in China
92
Trend of HIV-1 drug resistance in China: A systematic review and meta-analysis of data accumulated over 17 years (2001–2017)
93
(Q)SAR Models of HIV-1 protein inhibition by drug-like compounds
94
Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection
95
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance
96
Semen Extracellular Vesicles From HIV-1-Infected Individuals Inhibit HIV-1 Replication In Vitro, and Extracellular Vesicles Carry Antiretroviral Drugs In Vivo
97
Forecasting Prevalence of HIV-1 Integrase Strand Transfer Inhibitor (INSTI) Drug Resistance: A Modeling Study
98
Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection.
99
Discovery of dihydroxyindole-2-carboxylic acid derivatives as dual allosteric HIV-1 Integrase and Reverse Transcriptase associated Ribonuclease H inhibitors.
100
Mathematical analysis of an age-structured HIV-1 infection model with CTL immune response.
101
Preclinical optimization of gp120 entry-antagonists as anti-HIV-1 agents with improved cytotoxicity and ADME properties through rational design, synthesis, and antiviral evaluation.